Home › Therapeutic areas › Immunology › Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (14 companies)
Companies with an active program in Systemic Lupus Erythematosus.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| ACET | Adicet Bio | ImmunologyNeurology+2 Rare | 1 | Phase 1 | $28.6M | 8 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | $360M | 10 |
| AUTL | Autolus Therapeutics | HematologyImmunology+3 Rare | 1 | Approved | $341M | 12 |
| CABA | Cabaletta Bio | DermatologyImmunology+2 Rare | 1 | Phase 2 | $280M | 8 |
| IPSC | Century Therapeutics | ImmunologyMetabolic+1 Rare | 2 | Phase 1 | $304M | 9 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 2 | Phase 2 | $604M | 8 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 2 | NDA Submitted | $728M | 10 |
| FATE | Fate Therapeutics | ImmunologyOncology+1 Rare | 1 | Phase 2 | $224M | 10 |
| INAB | IN8bio | ImmunologyOncology | 1 | Phase 1 | $10.0M | 4 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 1 | Phase 2 | $11.2B | 5 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.27B | 11 |
| NKTX | Nkarta | ImmunologyNeurology+1 Rare | 1 | Phase 1 | $124M | 8 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 1 | NDA Submitted | $1.92B | 11 |
No companies match.